Brief: Matinas Biopharma Receives Qualified Infectious Disease Product And Fast Track Designations From U.S. FDA For Mat2203

Matinas BioPharma Holdings

25/07/2019 12:44

July 25 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA RECEIVES QUALIFIED INFECTIOUS DISEASE
PRODUCT
(QIDP) AND FAST TRACK DESIGNATIONS FROM U.S. FDA FOR MAT2203 FOR
THE TREATMENT OF CRYPTOCOCCAL MENINGITIS
    * MATINAS BIOPHARMA HOLDINGS - FDA DESIGNATED CO'S ORAL
AMPHOTERICIN B PRODUCT, AS A QUALIFIED INFECTIOUS DISEASE
PRODUCT WITH FAST TRACK STATUS

Source text for Eikon:  ID:nGNX3ZDmHW 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))